TGTX
TG Therapeutics, Inc.
Price Chart
Latest Quote
$52.55
+1.05 (+2.05%)
Current Price
| Previous Close | $51.50 |
| Open | $52.23 |
| Day High | $54.07 |
| Day Low | $52.00 |
| Volume | 1,187,512 |
Stock Information
| Shares Outstanding | 153.08M |
| Total Debt | $753.56M |
| Cash Equivalents | $514.43M |
| Revenue | $700.35M |
| Net Income | $461.90M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.05B |
| P/E Ratio | 18.38 |
| EPS (TTM) | $2.86 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.40B |
| Sales | $700.35M |
| Income | $461.90M |
| Book/sh | $4.11 |
| Cash/sh | $3.36 |
| Employees | 399 |
Financial Ratios
| Quick Ratio | 4.84 |
| Current Ratio | 5.81 |
| Debt/Eq | 129.23 |
| EPS Growth TTM | 290.90% |
Returns & Margins
| ROA | 8.55% |
| ROE | 112.60% |
| Gross Margin | 83.05% |
| Operating Margin | 16.98% |
| Profit Margin | 65.95% |
Ownership
| Insider Ownership | 7.47% |
| Institutional Ownership | 70.22% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 18.30 |
| PEG | 1.61 |
| P/S | 11.49 |
| P/B | 12.77 |
Analyst Data
| Recommendation | buy |
| Target Price | $48.00 |
Technical Indicators
| SMA20 | $43.10 |
| SMA50 | $39.72 |
| SMA200 | $33.65 |
| RSI | 90.56 |
| ATR | 2.6096 |
| Shares Float | 135.10M |
| Short Float | 26.61% |
| Short Ratio | 13.49 |
| Volatility | 1.68 |
| Rel Volume | 0.56 |
Performance History
| Week | +9.38% |
| Month | +33.29% |
| Quarter | +73.11% |
| 6 Months | +70.69% |
| YTD | +79.49% |
| Year | +50.16% |
| 3 Years | +91.25% |
| 5 Years | +39.14% |
| 10 Years | +648.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $52.56 | 1,187,526 |
| 2026-06-17 | $51.50 | 3,615,800 |
| 2026-06-16 | $50.54 | 1,993,300 |
| 2026-06-15 | $50.30 | 2,580,400 |
| 2026-06-12 | $49.52 | 2,546,800 |
| 2026-06-11 | $48.05 | 2,531,600 |
| 2026-06-10 | $46.62 | 5,113,200 |
| 2026-06-09 | $43.37 | 2,587,700 |
| 2026-06-08 | $40.95 | 1,555,900 |
| 2026-06-05 | $40.16 | 1,790,300 |
| 2026-06-04 | $40.56 | 2,343,500 |
| 2026-06-03 | $40.11 | 3,663,700 |
| 2026-06-02 | $36.64 | 1,528,300 |
| 2026-06-01 | $37.41 | 1,639,400 |
| 2026-05-29 | $37.94 | 1,224,800 |
| 2026-05-28 | $38.82 | 1,044,500 |
| 2026-05-27 | $39.20 | 1,575,900 |
| 2026-05-26 | $39.73 | 1,291,400 |
| 2026-05-22 | $38.87 | 1,357,300 |
| 2026-05-21 | $39.24 | 1,264,900 |
| 2026-05-20 | $39.76 | 1,413,900 |
| 2026-05-19 | $39.43 | 1,223,400 |
| 2026-05-18 | $39.48 | 1,602,600 |
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
đ° Latest News
TGTX Stock Continues Rally For 8 Straight Sessions On New BRIUMVI Clinical Data
Stocktwits âĸ 2026-06-17T21:26:54Z
TG Therapeutics Stock Is On A Hot Streak: Why It's Up 70% And Climbing
Investor's Business Daily âĸ 2026-06-17T12:00:03Z
Imviva Unveils Leukemia Data at EHA 2026 With 86% Response Rates
Exec Edge âĸ 2026-06-11T19:56:49Z
Dow Jones Futures Signal Market Bounce, But Then What? Oracle Dives, SpaceX IPO On Launch Pad
Investor's Business Daily âĸ 2026-06-11T12:10:43Z
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-06-11T09:12:00Z
Why This IBD Stock Of The Day, A Roche Rival, Just Broke Out To A Five-Year High
Investor's Business Daily âĸ 2026-06-10T20:57:19Z
Why TG Therapeutics (TGTX) Is Up 18.4% After Advancing AtâHome Subcutaneous BRIUMVI In MS Treatment
Simply Wall St. âĸ 2026-06-10T16:15:19Z
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
Zacks âĸ 2026-06-10T13:17:00Z
Dow Jones Futures Tumble As Trump Says Iran Will 'Have To Pay The Price'; CPI Inflation On Tap
Investor's Business Daily âĸ 2026-06-10T12:08:17Z
TGTX Stock Jumps 5% On Positive Early Data For At-Home BRIUMVI In Muscle Disease
Stocktwits âĸ 2026-06-09T20:34:27Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $100,714,000 | $38,486,000 | $14,131,000 | $265,000 |
| Cost Of Revenue | $100,714,000 | $38,486,000 | $14,131,000 | $265,000 |
| Total Revenue | $616,287,000 | $329,004,000 | $233,662,000 | $2,785,000 |
| Operating Revenue | $616,287,000 | $329,004,000 | $233,662,000 | $2,785,000 |
| Expenses | ||||
| Interest Expense | $26,727,000 | $24,028,000 | $12,615,000 | $10,191,000 |
| Total Expenses | $492,963,000 | $287,075,000 | $213,029,000 | $221,101,000 |
| Other Income Expense | $10,793,000 | $7,693,000 | $5,044,000 | $4,695,000 |
| Other Non Operating Income Expenses | $10,793,000 | $7,693,000 | $5,044,000 | $4,695,000 |
| Net Non Operating Interest Income Expense | $-26,727,000 | $-24,028,000 | $-12,615,000 | $-10,191,000 |
| Interest Expense Non Operating | $26,727,000 | $24,028,000 | $12,615,000 | $10,191,000 |
| Operating Expense | $392,249,000 | $248,589,000 | $198,898,000 | $220,836,000 |
| General And Administrative Expense | $232,034,000 | $154,298,000 | $122,706,000 | $95,484,000 |
| Selling And Marketing Expense | - | - | - | $64,046,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Net Interest Income | $-26,727,000 | $-24,028,000 | $-12,615,000 | $-10,191,000 |
| Normalized Income | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Net Income From Continuing And Discontinued Operation | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Total Operating Income As Reported | $123,324,000 | $41,929,000 | $20,633,000 | $-218,316,000 |
| Net Income Common Stockholders | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Net Income | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Net Income Including Noncontrolling Interests | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Net Income Continuous Operations | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Pretax Income | $107,390,000 | $25,594,000 | $13,062,000 | $-223,812,000 |
| Operating Income | $123,324,000 | $41,929,000 | $20,633,000 | $-218,316,000 |
| Gross Profit | $515,573,000 | $290,518,000 | $219,531,000 | $2,520,000 |
| Per Share | ||||
| Diluted EPS | $2.77 | $0.15 | $0.09 | $-1.46 |
| Basic EPS | $3.10 | $0.16 | $0.09 | $-1.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $134,361,000 | $49,902,000 | $26,100,000 | $-213,106,000 |
| Reconciled Depreciation | $244,000 | $280,000 | $423,000 | $515,000 |
| EBITDA (Bullshit earnings) | $134,361,000 | $49,902,000 | $26,100,000 | $-213,106,000 |
| EBIT | $134,117,000 | $49,622,000 | $25,677,000 | $-213,621,000 |
| Diluted Average Shares | $161,412,746 | $160,336,051 | $148,508,465 | $135,411,258 |
| Basic Average Shares | $144,316,786 | $145,317,418 | $141,955,112 | $135,411,258 |
| Diluted NI Availto Com Stockholders | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Tax Provision | $-339,789,000 | $2,211,000 | $390,000 | $0 |
| Research And Development | $160,215,000 | $94,291,000 | $76,192,000 | $125,352,000 |
| Selling General And Administration | $232,034,000 | $154,298,000 | $122,706,000 | $95,484,000 |
| Other Gand A | $183,981,000 | $122,917,000 | $97,783,000 | $64,046,000 |
| Salaries And Wages | $48,053,000 | $31,381,000 | $24,923,000 | $31,438,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $648,020,000 | $222,364,000 | $160,502,000 | $57,788,000 |
| Total Assets | $1,063,253,000 | $577,690,000 | $329,587,000 | $193,572,000 |
| Total Non Current Assets | $432,489,000 | $11,331,000 | $11,644,000 | $25,298,000 |
| Other Non Current Assets | $3,386,000 | $3,372,000 | $3,594,000 | $1,273,000 |
| Non Current Deferred Assets | $348,000,000 | $0 | - | - |
| Non Current Deferred Taxes Assets | $348,000,000 | $0 | - | - |
| Investmentin Financial Assets | $59,136,000 | $808,000 | $0 | $12,404,000 |
| Current Assets | $630,764,000 | $566,359,000 | $317,943,000 | $168,274,000 |
| Other Current Assets | $57,580,000 | $15,716,000 | $9,519,000 | $2,359,000 |
| Inventory | $125,586,000 | $110,458,000 | $39,823,000 | $0 |
| Receivables | $305,628,000 | $129,185,000 | $51,093,000 | $0 |
| Accounts Receivable | $305,628,000 | $129,185,000 | $51,093,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $141,970,000 | $311,000,000 | $217,508,000 | $161,678,000 |
| Cash And Cash Equivalents | $79,148,000 | $179,894,000 | $92,933,000 | $102,304,000 |
| Goodwill And Other Intangible Assets | - | - | $799,000 | $799,000 |
| Prepaid Assets | - | - | $4,183,000 | $4,237,000 |
| Debt | ||||
| Net Debt | $166,497,000 | $64,535,000 | $7,185,000 | - |
| Total Debt | $253,710,000 | $253,719,000 | $110,795,000 | $83,060,000 |
| Long Term Debt And Capital Lease Obligation | $252,666,000 | $252,562,000 | $109,349,000 | $81,479,000 |
| Long Term Debt | $245,645,000 | $244,429,000 | $100,118,000 | $71,135,000 |
| Current Debt And Capital Lease Obligation | $1,044,000 | $1,157,000 | $1,446,000 | $1,581,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $415,233,000 | $355,326,000 | $169,085,000 | $134,985,000 |
| Total Non Current Liabilities Net Minority Interest | $261,473,000 | $264,647,000 | $115,365,000 | $81,784,000 |
| Non Current Deferred Liabilities | $8,807,000 | $12,085,000 | $6,016,000 | $305,000 |
| Current Liabilities | $153,760,000 | $90,679,000 | $53,720,000 | $53,201,000 |
| Other Current Liabilities | $2,124,000 | $4,627,000 | $1,479,000 | $1,169,000 |
| Current Deferred Liabilities | $21,234,000 | $11,414,000 | $152,000 | - |
| Payables And Accrued Expenses | $107,508,000 | $58,296,000 | $38,471,000 | $42,019,000 |
| Equity | ||||
| Common Stock Equity | $648,020,000 | $222,364,000 | $160,502,000 | $58,587,000 |
| Total Equity Gross Minority Interest | $648,020,000 | $222,364,000 | $160,502,000 | $58,587,000 |
| Stockholders Equity | $648,020,000 | $222,364,000 | $160,502,000 | $58,587,000 |
| Retained Earnings | $-1,082,015,000 | $-1,529,194,000 | $-1,552,577,000 | $-1,527,033,000 |
| Long Term Equity Investment | $15,689,000 | $0 | - | - |
| Other | ||||
| Treasury Shares Number | $3,543,643 | $367,903 | $41,309 | $41,309 |
| Ordinary Shares Number | $155,305,953 | $155,836,256 | $151,424,289 | $146,385,388 |
| Share Issued | $158,849,596 | $156,204,159 | $151,465,598 | $146,426,697 |
| Tangible Book Value | $648,020,000 | $222,364,000 | $160,502,000 | $57,788,000 |
| Invested Capital | $893,665,000 | $466,793,000 | $260,620,000 | $129,722,000 |
| Working Capital | $477,004,000 | $475,680,000 | $264,223,000 | $115,073,000 |
| Capital Lease Obligations | $8,065,000 | $9,290,000 | $10,677,000 | $11,925,000 |
| Total Capitalization | $893,665,000 | $466,793,000 | $260,620,000 | $129,722,000 |
| Treasury Stock | $100,234,000 | $8,994,000 | $234,000 | $234,000 |
| Additional Paid In Capital | $1,830,110,000 | $1,760,396,000 | $1,713,162,000 | $1,585,708,000 |
| Capital Stock | $159,000 | $156,000 | $151,000 | $146,000 |
| Common Stock | $159,000 | $156,000 | $151,000 | $146,000 |
| Non Current Deferred Revenue | $8,807,000 | $12,085,000 | $6,016,000 | $305,000 |
| Long Term Capital Lease Obligation | $7,021,000 | $8,133,000 | $9,231,000 | $10,344,000 |
| Current Deferred Revenue | $21,234,000 | $11,414,000 | $152,000 | - |
| Current Capital Lease Obligation | $1,044,000 | $1,157,000 | $1,446,000 | $1,581,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $21,850,000 | $15,185,000 | $12,172,000 | $8,432,000 |
| Investments And Advances | $74,825,000 | $808,000 | $0 | $12,404,000 |
| Held To Maturity Securities | $59,136,000 | $808,000 | $0 | $12,404,000 |
| Net PPE | $6,278,000 | $7,151,000 | $8,050,000 | $10,822,000 |
| Gross PPE | $6,278,000 | $7,151,000 | $8,050,000 | $10,822,000 |
| Other Properties | $6,278,000 | $7,151,000 | $8,050,000 | $9,195,000 |
| Other Short Term Investments | $62,822,000 | $131,106,000 | $124,575,000 | $59,374,000 |
| Goodwill | - | - | $799,000 | $799,000 |
| Leases | - | - | $1,415,000 | $1,627,000 |
| Properties | - | - | $0 | $0 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-24,986,000 | $-40,562,000 | $-31,413,000 | $-176,184,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-24,772,000 | $-40,517,000 | $-31,413,000 | $-176,170,000 |
| Cash Flow From Continuing Operating Activities | $-24,772,000 | $-40,517,000 | $-31,413,000 | $-176,170,000 |
| Operating Gains Losses | - | $4,607,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-214,000 | $-45,000 | - | $-14,000 |
| Investing Cash Flow | $13,799,000 | $-1,036,000 | $-50,651,000 | $-20,013,000 |
| Cash Flow From Continuing Investing Activities | $13,799,000 | $-1,036,000 | $-50,651,000 | $-20,013,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-91,240,000 | $-8,760,000 | $0 | $0 |
| Issuance Of Capital Stock | $0 | $0 | $46,296,000 | $0 |
| Financing Cash Flow | $-89,729,000 | $128,527,000 | $72,705,000 | $-391,000 |
| Cash Flow From Continuing Financing Activities | $-89,729,000 | $128,527,000 | $72,705,000 | $-391,000 |
| Net Common Stock Issuance | $-91,240,000 | $-8,760,000 | $46,296,000 | $0 |
| Common Stock Issuance | $0 | $0 | $46,296,000 | $0 |
| Net Other Financing Charges | - | $-889,000 | $-125,000 | - |
| Cash Dividends Paid | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $-107,553,000 | $0 | $-975,000 |
| Issuance Of Debt | $0 | $244,815,000 | $25,000,000 | $0 |
| Interest Paid Supplemental Data | $24,249,000 | $18,470,000 | $8,771,000 | $5,445,000 |
| Income Tax Paid Supplemental Data | $7,879,000 | $500,000 | $0 | $0 |
| End Cash Position | $80,490,000 | $181,192,000 | $94,218,000 | $103,577,000 |
| Beginning Cash Position | $181,192,000 | $94,218,000 | $103,577,000 | $300,151,000 |
| Changes In Cash | $-100,702,000 | $86,974,000 | $-9,359,000 | $-196,574,000 |
| Proceeds From Stock Option Exercised | $1,511,000 | $914,000 | $1,534,000 | $584,000 |
| Common Stock Payments | $-91,240,000 | $-8,760,000 | $0 | $0 |
| Net Issuance Payments Of Debt | $0 | $137,262,000 | $25,000,000 | $-975,000 |
| Net Long Term Debt Issuance | $0 | $137,262,000 | $25,000,000 | $-975,000 |
| Long Term Debt Payments | $0 | $-107,553,000 | $0 | $-975,000 |
| Long Term Debt Issuance | $0 | $244,815,000 | $25,000,000 | $0 |
| Net Investment Purchase And Sale | $14,013,000 | $-991,000 | $-50,651,000 | $-19,999,000 |
| Sale Of Investment | $237,500,000 | $310,900,000 | $96,229,000 | $87,275,000 |
| Purchase Of Investment | $-223,487,000 | $-311,891,000 | $-146,880,000 | $-107,274,000 |
| Net PPE Purchase And Sale | $-214,000 | $-45,000 | $0 | $-14,000 |
| Purchase Of PPE | $-214,000 | $-45,000 | $0 | $-14,000 |
| Change In Working Capital | $-194,537,000 | $-109,297,000 | $-84,659,000 | $-1,647,000 |
| Change In Other Working Capital | $6,390,000 | $17,483,000 | $5,711,000 | $-152,000 |
| Change In Other Current Liabilities | $-4,480,000 | $1,641,000 | $300,000 | $-55,000 |
| Change In Other Current Assets | $-42,430,000 | $-6,316,000 | $-2,831,000 | $8,181,000 |
| Change In Payables And Accrued Expense | $55,878,000 | $22,838,000 | $192,000 | $-11,010,000 |
| Change In Inventory | $-33,452,000 | $-66,851,000 | $-36,938,000 | $0 |
| Change In Receivables | $-176,443,000 | $-78,092,000 | $-51,093,000 | $1,389,000 |
| Changes In Account Receivables | $-176,443,000 | $-78,092,000 | $-51,093,000 | $1,389,000 |
| Other Non Cash Items | $2,991,000 | $4,199,000 | $4,454,000 | $4,443,000 |
| Stock Based Compensation | $64,670,000 | $42,541,000 | $37,933,000 | $44,662,000 |
| Unrealized Gain Loss On Investment Securities | $298,000 | $754,000 | $0 | $0 |
| Provisionand Write Offof Assets | $6,171,000 | $0 | $0 | - |
| Amortization Of Securities | $-3,788,000 | $-6,984,000 | $-2,236,000 | $-331,000 |
| Deferred Tax | $-348,000,000 | $0 | $0 | - |
| Deferred Income Tax | $-348,000,000 | $0 | $0 | - |
| Depreciation Amortization Depletion | $244,000 | $280,000 | $423,000 | $515,000 |
| Depreciation And Amortization | $244,000 | $280,000 | $423,000 | $515,000 |
| Depreciation | $244,000 | $280,000 | $423,000 | $515,000 |
| Net Income From Continuing Operations | $447,179,000 | $23,383,000 | $12,672,000 | $-223,812,000 |
| Interest Paid Cff | - | - | - | - |
Fetched: 2026-06-17